Compare Stocks: SCNX, INCR, HRTX, and NTRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$0.35 +1.8%	$0.40	$0.30 ▼ $1.58	$65.29M	1.61	2.66 million shs	1.06 million shs
INCR InterCure	$5.39 -0.6%	$4.98	$3.40 ▼ $8.45	$59.28M	1.42	43,236 shs	9,244 shs
NTRB Nutriband	$6.10 +2.2%	$3.58	$2.80 ▼ $8.63	$72.57M	2.03	41,959 shs	109,679 shs
SCNX Scienture	$0.36 -2.5%	$0.39	$0.24 ▼ $2.60	$15.32M	3.25	3.48 million shs	210,964 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	+1.77%	+11.11%	-28.69%	-14.30%	-73.08%
INCR InterCure	-0.55%	-2.18%	+10.00%	+26.81%	-33.66%
NTRB Nutriband	+2.18%	+40.55%	+96.14%	+78.89%	-2.56%
SCNX Scienture	-2.49%	-0.90%	-4.31%	+3.09%	-59.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$0.35 +1.8%	$0.40	$0.30 ▼ $1.58	$65.29M	1.61	2.66 million shs	1.06 million shs
INCR InterCure	$5.39 -0.6%	$4.98	$3.40 ▼ $8.45	$59.28M	1.42	43,236 shs	9,244 shs
NTRB Nutriband	$6.10 +2.2%	$3.58	$2.80 ▼ $8.63	$72.57M	2.03	41,959 shs	109,679 shs
SCNX Scienture	$0.36 -2.5%	$0.39	$0.24 ▼ $2.60	$15.32M	3.25	3.48 million shs	210,964 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	+1.77%	+11.11%	-28.69%	-14.30%	-73.08%
INCR InterCure	-0.55%	-2.18%	+10.00%	+26.81%	-33.66%
NTRB Nutriband	+2.18%	+40.55%	+96.14%	+78.89%	-2.56%
SCNX Scienture	-2.49%	-0.90%	-4.31%	+3.09%	-59.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	2.00	Hold	$2.00	471.43% Upside
INCR InterCure	1.00	Sell	N/A	N/A
NTRB Nutriband	1.50	Reduce	N/A	N/A
SCNX Scienture	2.00	Hold	$1.50	312.43% Upside

Current Analyst Ratings Breakdown

Latest SCNX, INCR, HRTX, and NTRB Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/3/2026	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	HRTX Heron Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	INCR InterCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	INCR InterCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/17/2026	NTRB Nutriband	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$154.90M	0.43	N/A	N/A	$0.07 per share	5.00
INCR InterCure	$78.47M	0.75	N/A	N/A	$10.53 per share	0.51
NTRB Nutriband	$1.62M	45.84	N/A	N/A	$0.55 per share	11.09
SCNX Scienture	$430K	34.73	N/A	N/A	$1.73 per share	0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-293.02%	-10.00%	11/3/2026 (Estimated)
INCR InterCure	-$10.37M	$0.15	35.93	N/A	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	-$8.23M	-$0.53	N/A	N/A	N/A	-430.35%	-103.36%	-91.38%	9/30/2026 (Estimated)
SCNX Scienture	-$41.51M	-$2.10	N/A	N/A	N/A	N/A	-53.51%	-42.47%	11/12/2026 (Estimated)

Latest SCNX, INCR, HRTX, and NTRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q2 2027	NTRB Nutriband	N/A	-$0.07	N/A	-$0.07	N/A	$0.44 million
8/13/2026	Q2 2026	SCNX Scienture	-$0.09	-$0.07	+$0.02	-$0.07	$1.96 million	$0.34 million
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million
6/11/2026	Q1 2027	NTRB Nutriband	N/A	-$0.10	N/A	-$0.10	N/A	$0.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	24.35	2.49	1.51
INCR InterCure	0.20	1.48	0.97
NTRB Nutriband	N/A	5.26	5.11
SCNX Scienture	0.15	3.04	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
INCR InterCure	8.34%
NTRB Nutriband	19.70%
SCNX Scienture	5.68%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	6.10%
INCR InterCure	N/A
NTRB Nutriband	52.21%
SCNX Scienture	21.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	189.85 million	178.27 million	Optionable
INCR InterCure	350	10.94 million	N/A	Optionable
NTRB Nutriband	10	12.16 million	5.81 million	Not Optionable
SCNX Scienture	N/A	41.06 million	32.28 million	N/A

SCNX, INCR, HRTX, and NTRB Headlines

Recent News About These Companies

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses

August 14, 2026 | quiverquant.comQ

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

August 14, 2026 | globenewswire.com

Scienture Holdings Stock Price History

August 12, 2026 | investing.com

Scienture launches Rezenopy as second FDA-approved commercial product

August 12, 2026 | msn.com

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

August 12, 2026 | globenewswire.com

Scienture Holdings纳洛酮鼻喷雾剂7月将向美批发商发货

July 28, 2026 | finance.sina.com.cnF

Scienture Holdings stock jumps over 20% pre-market: Here's why

July 10, 2026 | msn.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | finance.yahoo.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | globenewswire.com

SCNX Share News Today

July 4, 2026 | uk.investing.com

Scienture Holdings (SCNX) Stock Forecast & Price Target

June 25, 2026 | investing.com

Scienture Holdings Stock Short Interest Report | NASDAQ:SCNX | Benzinga

June 24, 2026 | benzinga.com

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

June 18, 2026 | globenewswire.com

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)

June 17, 2026 | theglobeandmail.com

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

June 9, 2026 | globenewswire.com

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

June 4, 2026 | accessnewswire.comA

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

June 2, 2026 | globenewswire.com

Scienture Holdings Announces CFO Resignation, Names Interim Successor

May 29, 2026 | tipranks.com

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

May 18, 2026 | globenewswire.com

Scienture Holdings Inc SCNX

May 12, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SCNX, INCR, HRTX, and NTRB Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$0.35 +0.01 (+1.77%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$0.35 0.00 (-0.86%)

As of 07:36 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

InterCure NASDAQ:INCR

$5.39 -0.03 (-0.55%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$5.41 +0.02 (+0.37%)

As of 09/8/2026 07:30 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Nutriband NASDAQ:NTRB

$6.10 +0.13 (+2.18%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$6.10 0.00 (-0.08%)

As of 07:12 AM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Scienture NASDAQ:SCNX

$0.36 -0.01 (-2.49%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$0.32 -0.04 (-11.19%)

As of 07:40 AM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, INCR, HRTX, and NTRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, INCR, HRTX, and NTRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, INCR, HRTX, and NTRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SCNX, INCR, HRTX, and NTRB Company Descriptions

Heron Therapeutics NASDAQ:HRTX

InterCure NASDAQ:INCR

Nutriband NASDAQ:NTRB

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, INCR, HRTX, and NTRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, INCR, HRTX, and NTRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, INCR, HRTX, and NTRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SCNX, INCR, HRTX, and NTRB Company Descriptions

Heron Therapeutics NASDAQ:HRTX

InterCure NASDAQ:INCR

Nutriband NASDAQ:NTRB

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools